MDM2/p53 Protein Expression in the Development of Colorectal Adenocarcinoma

Ghada Abdel-Fattah, Boris Yoffe, Bhuvaneswari Krishnan, Vladimir Khaoustov, Kamal Itani

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The murine double minutes 2 (MDM2) oncoprotein inhibits p53-mediated tumor suppression. MDM2 has been shown to be overexpressed in sarcomas and more recently was implicated in the pathogenesis of carcinomas. The purpose of this study was to determine the expression pattern of MDM2 in adenomas and colorectal adenocarcinomas and decide whether there is a correlation between MDM2 and pS3 protein status. Paraffin-embedded tissues from 52 colorectal cancer (CRC) specimens and their adjacent normal tissue (N-CRC) were studied, In addition, 56 sporadic adenomas were investigated for the immunohistochemical expression of MDM2 and p53 proteins. Immunoreactivity of p53 indicating p53 gene mutation (p53+) was significantly higher in CRC (44%) compared to adenomas (23.2%) (P<0.01). None of the N-CRC specimens expressed the immunoreactive p53 protein. MDM2 overexpression (MDM2+) was similar in adenomas (30.3%) and CRC (25%), but only 2 (3.8%) of 52 N-CRC specimens showed overexpression of MDM2. In most cases MDM2 expression was associated with negative p53 expression (wild-type p53) in both adenomas (r = 0.59, P <0.001) and CRC (r = 0.69, P<0.0001). No correlation was found between MDM2, p53 expression, and either the histologic grade, nodal stage or morphology of the tumors. There is greater p53 mutation in CRC compared to adenomas and N-CRC. The data indicate that MDM2 is overexpressed in CRC and is significantly associated with wild-type p53 compared to N-CRC specimens from the same patient. The MDM2 expression pattern is similar in adenomas and CRC, which may suggest that MDM2 overexpression is an early event in the progression of CRC.

Original languageEnglish (US)
Pages (from-to)109-114
Number of pages6
JournalJournal of Gastrointestinal Surgery
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Proto-Oncogene Proteins c-mdm2
Colorectal Neoplasms
Adenocarcinoma
Adenoma
Tumor Suppressor Protein p53
Mutation
p53 Genes

Keywords

  • Colorectal cancer
  • Mdm2 oncogene
  • P53

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

MDM2/p53 Protein Expression in the Development of Colorectal Adenocarcinoma. / Abdel-Fattah, Ghada; Yoffe, Boris; Krishnan, Bhuvaneswari; Khaoustov, Vladimir; Itani, Kamal.

In: Journal of Gastrointestinal Surgery, Vol. 4, No. 1, 01.01.2000, p. 109-114.

Research output: Contribution to journalArticle

Abdel-Fattah, G, Yoffe, B, Krishnan, B, Khaoustov, V & Itani, K 2000, 'MDM2/p53 Protein Expression in the Development of Colorectal Adenocarcinoma', Journal of Gastrointestinal Surgery, vol. 4, no. 1, pp. 109-114. https://doi.org/10.1016/S1091-255X(00)80041-4
Abdel-Fattah, Ghada ; Yoffe, Boris ; Krishnan, Bhuvaneswari ; Khaoustov, Vladimir ; Itani, Kamal. / MDM2/p53 Protein Expression in the Development of Colorectal Adenocarcinoma. In: Journal of Gastrointestinal Surgery. 2000 ; Vol. 4, No. 1. pp. 109-114.
@article{bd0c7ac9c41b4306938970f29d42f9be,
title = "MDM2/p53 Protein Expression in the Development of Colorectal Adenocarcinoma",
abstract = "The murine double minutes 2 (MDM2) oncoprotein inhibits p53-mediated tumor suppression. MDM2 has been shown to be overexpressed in sarcomas and more recently was implicated in the pathogenesis of carcinomas. The purpose of this study was to determine the expression pattern of MDM2 in adenomas and colorectal adenocarcinomas and decide whether there is a correlation between MDM2 and pS3 protein status. Paraffin-embedded tissues from 52 colorectal cancer (CRC) specimens and their adjacent normal tissue (N-CRC) were studied, In addition, 56 sporadic adenomas were investigated for the immunohistochemical expression of MDM2 and p53 proteins. Immunoreactivity of p53 indicating p53 gene mutation (p53+) was significantly higher in CRC (44{\%}) compared to adenomas (23.2{\%}) (P<0.01). None of the N-CRC specimens expressed the immunoreactive p53 protein. MDM2 overexpression (MDM2+) was similar in adenomas (30.3{\%}) and CRC (25{\%}), but only 2 (3.8{\%}) of 52 N-CRC specimens showed overexpression of MDM2. In most cases MDM2 expression was associated with negative p53 expression (wild-type p53) in both adenomas (r = 0.59, P <0.001) and CRC (r = 0.69, P<0.0001). No correlation was found between MDM2, p53 expression, and either the histologic grade, nodal stage or morphology of the tumors. There is greater p53 mutation in CRC compared to adenomas and N-CRC. The data indicate that MDM2 is overexpressed in CRC and is significantly associated with wild-type p53 compared to N-CRC specimens from the same patient. The MDM2 expression pattern is similar in adenomas and CRC, which may suggest that MDM2 overexpression is an early event in the progression of CRC.",
keywords = "Colorectal cancer, Mdm2 oncogene, P53",
author = "Ghada Abdel-Fattah and Boris Yoffe and Bhuvaneswari Krishnan and Vladimir Khaoustov and Kamal Itani",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S1091-255X(00)80041-4",
language = "English (US)",
volume = "4",
pages = "109--114",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - MDM2/p53 Protein Expression in the Development of Colorectal Adenocarcinoma

AU - Abdel-Fattah, Ghada

AU - Yoffe, Boris

AU - Krishnan, Bhuvaneswari

AU - Khaoustov, Vladimir

AU - Itani, Kamal

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The murine double minutes 2 (MDM2) oncoprotein inhibits p53-mediated tumor suppression. MDM2 has been shown to be overexpressed in sarcomas and more recently was implicated in the pathogenesis of carcinomas. The purpose of this study was to determine the expression pattern of MDM2 in adenomas and colorectal adenocarcinomas and decide whether there is a correlation between MDM2 and pS3 protein status. Paraffin-embedded tissues from 52 colorectal cancer (CRC) specimens and their adjacent normal tissue (N-CRC) were studied, In addition, 56 sporadic adenomas were investigated for the immunohistochemical expression of MDM2 and p53 proteins. Immunoreactivity of p53 indicating p53 gene mutation (p53+) was significantly higher in CRC (44%) compared to adenomas (23.2%) (P<0.01). None of the N-CRC specimens expressed the immunoreactive p53 protein. MDM2 overexpression (MDM2+) was similar in adenomas (30.3%) and CRC (25%), but only 2 (3.8%) of 52 N-CRC specimens showed overexpression of MDM2. In most cases MDM2 expression was associated with negative p53 expression (wild-type p53) in both adenomas (r = 0.59, P <0.001) and CRC (r = 0.69, P<0.0001). No correlation was found between MDM2, p53 expression, and either the histologic grade, nodal stage or morphology of the tumors. There is greater p53 mutation in CRC compared to adenomas and N-CRC. The data indicate that MDM2 is overexpressed in CRC and is significantly associated with wild-type p53 compared to N-CRC specimens from the same patient. The MDM2 expression pattern is similar in adenomas and CRC, which may suggest that MDM2 overexpression is an early event in the progression of CRC.

AB - The murine double minutes 2 (MDM2) oncoprotein inhibits p53-mediated tumor suppression. MDM2 has been shown to be overexpressed in sarcomas and more recently was implicated in the pathogenesis of carcinomas. The purpose of this study was to determine the expression pattern of MDM2 in adenomas and colorectal adenocarcinomas and decide whether there is a correlation between MDM2 and pS3 protein status. Paraffin-embedded tissues from 52 colorectal cancer (CRC) specimens and their adjacent normal tissue (N-CRC) were studied, In addition, 56 sporadic adenomas were investigated for the immunohistochemical expression of MDM2 and p53 proteins. Immunoreactivity of p53 indicating p53 gene mutation (p53+) was significantly higher in CRC (44%) compared to adenomas (23.2%) (P<0.01). None of the N-CRC specimens expressed the immunoreactive p53 protein. MDM2 overexpression (MDM2+) was similar in adenomas (30.3%) and CRC (25%), but only 2 (3.8%) of 52 N-CRC specimens showed overexpression of MDM2. In most cases MDM2 expression was associated with negative p53 expression (wild-type p53) in both adenomas (r = 0.59, P <0.001) and CRC (r = 0.69, P<0.0001). No correlation was found between MDM2, p53 expression, and either the histologic grade, nodal stage or morphology of the tumors. There is greater p53 mutation in CRC compared to adenomas and N-CRC. The data indicate that MDM2 is overexpressed in CRC and is significantly associated with wild-type p53 compared to N-CRC specimens from the same patient. The MDM2 expression pattern is similar in adenomas and CRC, which may suggest that MDM2 overexpression is an early event in the progression of CRC.

KW - Colorectal cancer

KW - Mdm2 oncogene

KW - P53

UR - http://www.scopus.com/inward/record.url?scp=0033630298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033630298&partnerID=8YFLogxK

U2 - 10.1016/S1091-255X(00)80041-4

DO - 10.1016/S1091-255X(00)80041-4

M3 - Article

C2 - 10631371

AN - SCOPUS:0033630298

VL - 4

SP - 109

EP - 114

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 1

ER -